SEC Form 4 · accession 0001179110-19-003030
MEDICINES CO /DE · MDCO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Clive Meanwell
Officer — Chief Innovation Officer · Director
Period of report
Feb 28, 2019
Accepted (ET)
Mar 4, 2019 · 4:23 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001113481
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Feb 28, 2019 | A | 317 | $20.97 | A | 302,726 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock option (right to buy)F2 | $25.41 | Mar 1, 2019 | A | 95,000 | A | — | Mar 1, 2029 | Common Stock | 95,000 | 95,000 | D |
Explanation of responses
- F1Shares of common stock acquired pursuant to The Medicines Company Employee Stock Purchase Plan ('ESPP') for the ESPP purchase period beginning September 1, 2018 and ending February 28, 2019. In accordance with the terms of the ESPP, these shares were purchased based on 85% of the fair market value closing price of the issuer's common stock on February 28, 2019.
- F2The option vests in forty-eight equal installments beginning April 1, 2019.